Mikael Dolsten

Dr. Dolsten most recently served as Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer Inc., where he led global R&D strategy and portfolio advancement for more than 16 years. A physician–scientist and biopharma leader, Dr. Dolsten has been instrumental in the development of breakthrough innovations spanning small molecules, biologics, gene therapies, and vaccines—including leading Pfizer's scientific response to the COVID-19 pandemic. His leadership has shaped portfolios at Boehringer Ingelheim, AstraZeneca, and Wyeth, and he has contributed to corporate transactions exceeding $100 billion in value. He has also contributed to more than 36 drug approvals, many representing breakthroughs in the oncology field, during his tenure as leader of Pfizer global R&D-Medical.

Dr. Dolsten currently serves on the public boards of Agilent Technologies and Rocket Pharmaceuticals and holds advisory roles with leading investment and innovation groups including Blackstone Life Sciences, GV (formerly Google Ventures), Bain & Company, and Formation Bio. He also advises and serves on the boards of several private biotechnology companies, including Arbor Biotechnologies, Orbis Medicines, Immunai, FairJourney Biologics, Orogen Therapeutics, Quarry Thera, and Chai Discovery. He is a Visiting Professor at Lund University and a member of the Royal Swedish Academy of Engineering Sciences, and he has advised U.S. and U.K. leadership on public health and pandemic preparedness.